Latest Cambodian News
TORONTO, October 1, 2014 /PRNewswire/ — To celebrate the upcoming 65th anniversary of the founding of the People’s Republic of China and to create a moment of warmth among the members of the city’s Chinese community, a public-benefi…
SHANGHAI, October 1, 2014 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (WuXi) (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in C…
— Strong brand image and a wide product portfolio that caters to a broad range of end-user applications and industries
LONDON, Oct. 1, 2014 /PRNewswire/ — Based on its recent analysis of the head protection market, Frost & Sullivan recognizes JSP with the 2014 European Frost & Sullivan Market Leadership Award for capturing the highest market share within its industry. JSP has outpaced the overall personal protection equipment (PPE) market to maintain its hold on the market leadership position in the head protection market. It has achieved this distinction through intense innovation, which has resulted in new products and designs that enhance end-user comfort and safety.
JSP’s significant investments in R&D and manufacturing have yielded market-leading hard hat designs, especially the Mk8 Evolution® helmet, which is the only industrial helmet in the world that meets and exceeds the stringent EN14052 standard. The EN14052 standard requires the helmet to withstand 100 Joules of crown impact and side impact of 50 Joules to an angle of up to 60 degrees from vertical in a 360 degree radius around the shell.
As comfort is a key factor in the head protection market, the weight of a hard hat is crucial. Keeping this in mind, JSP developed the EVOLite® hard hat, which weighs approximately 285g and is considered the lightest safety helmet in its class. EVOLite® helps increase compliance rates among end users and still meets the specifications of the EN397 standard (withstand impact of 49 Joules).
The Evo3® hard hat, introduced in 2011, takes much of its design from the Mk8 Evolution® helmet, making it the best performing EN397 helmet in the market. It is designed to operate across multiple end-user sectors, in temperature conditions ranging from -50° C to +50° C. JSP also launched the Skyworker™ EN12492 Mountaineering Helmet, which gives enhanced crown and side impact protection. Its other notable products include Evo® 6100 Full Brim hard hat, which is used especially in hotter conditions, and the Hard Cap A1+™, which is the most protective baseball style EN812 bump cap in the market.
“Recognizing that product quality is a key differentiating factor in the highly competitive European head protection market, the company does not outsource its research or product development,” said Frost & Sullivan Research Analyst Shray Sharma. “JSP maintains a constant focus on using new materials and manufacturing technologies. It has also acknowledged the rising trend of sustainability by developing hard hats made from fully recyclable, UV-stabilised, high-density polyethylene.”
JSP has a wide breadth of head protection hard hats and cover more standards than its rival companies. It has focused on developing its Evolution® hard hat line by adding new features and specifications that enhance product value. A key selling point of the new Evolution® range is the harness that comes with 3D Precision Fitting. This enables a perfect fit to the end user by regulating not only circumference but also depth of the harness fit giving excellent retention and stability.
JSP operates in the middle and higher tier segment of the market, and its hard hats are renowned for their quality and comfort. To combat the threat of counterfeits, it implemented a unique coding system for each of its hard hats, wherein its online JSPCHECK™ system helps establish the validity of the product.
Furthermore, to help users choose the right kind of hat, JSP introduced the ‘JSP Star Guide’, which rates the hats for the level of protection they provide. Alongside the rating is a list of standards to which the product conforms and the industry vertical markets where that specific hard hat is typically used.
JSP has also integrated several products to enhance the value customers derive from its products. For instance, the EVOLite® and EVO3® hard hats can be customised to be used with EVOSpec® safety eyewear. The company has a wide range of cap lamps and introduced an anti-rust, stainless steel lamp bracket for mining hard hats.
Similarly, the InterGP™ and InterEx™ range of hearing protection attachments provide integrated hearing protection, while the Surefit™ visor carrier system enables polycarbonate, acetate and forestry visor shields to be mounted onto the helmet. It also offers a range of helmet liners, which provide warmth at low temperatures and a sun protector, which shields the end user’s neck from prolonged exposures to sunlight. Additionally, JSP has pioneered the use of CR2 reflective stickers on hard hats.
“Owing to the expansion of its manufacturing capabilities, JSP currently operates in over 90 countries across the globe and is the largest head protection manufacturer in Europe,” noted Sharma. “By structuring itself to increase manufacturing, invest in R&D and enhance supply chain efficiency, JSP has addressed key unmet needs in the head protection market.”
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About JSP
Established in 1964, JSP is Europe’s leading independent manufacturer of “above the neck” Personal Protective Equipment (PPE) and acknowledged leader in industrial head protection. With its Headquarters and PPE Innovation Centre in Oxford, JSP manufactures on three continents and exports to over 90 countries.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation
Contact:
Lucy Hearnden – JSP Ltd
Customer Services Administrator
Lucy.Hearnden@jsp.co.uk
P: +44 1993 824000
Melanie Parkinson – Frost & Sullivan
Best Practices
Melanie.Parkinson@frost.com
P: +44 (0)20 7915 7867
 |
ORLANDO, Florida, Oct. 1, 2014 /PRNewswire/ — CORD:USE Cord Blood Bank – www.corduse.com – is pleased to announce that it has entered into an Equity and Exclusive Services Agreement with Tianhe Stem Cell Biotechnologies, Inc. (Tianhe) which has licensed a series of patented technologies for the isolation of human cord blood-derived multipotent stem cells for possible clinical applications. Tianhe is performing Phase I/II clinical trials in China and Spain using Tianhe’s Stem Cell Educator Therapy showing that the therapy is safe. In patients with moderate or severe Type 1 Diabetes (T1D), a single treatment produced lasting improvement in metabolic control. Trial results demonstrated improvement lasting three years following a single treatment. Trials also revealed improvement in 80% of patients who have Type 2 Diabetes (T2D). Initial results indicate Stem Cell Educator Therapy reverses autoimmunity and promotes regeneration of islet beta-cells with the goal of producing a treatment for T1D and T2D, as well as other autoimmune diseases.
“Tianhe is honored and thrilled to partner with CORD:USE. We have received cord blood from many banks around the nation and world, but we have found that the cord blood provided to us by CORD:USE has the highest quality of any cord blood that we have received,” said Dr. Yong Zhao, President of Tianhe.
“From CORD:USE’s inception, and since we have brought together many of the world leaders in cord blood banking, research and transplantation to our team, our goal was to provide high quality, life-saving therapies for patients in need. This partnership signifies our commitment to this mission and to the cutting edge research and clinical trials necessary to provide new therapies that could benefit large populations of patients,” said Edward Guindi, MD, President and CEO of CORD:USE.
The American Diabetes Association estimates that in the U.S. alone as many as 25 million people are afflicted with diabetes. The World Health Organization (WHO) reports that approximately 347 million people have diabetes worldwide and the WHO projects that it will be the 7th leading cause of death by 2030. Diabetes and its associated complications substantially affect the quality of life and create significant economic burden. Additionally, the American Autoimmune Related Diseases Association cites that 50 million Americans suffer from an autoimmune disease.
“Umbilical cord blood is a rich source of stem and progenitor cells as well as immune cell populations with tremendous potential in the treatment of many diseases including diabetes and other autoimmune diseases. CORD:USE strives to be the best in class in cord blood banking while being instrumental in the development of such new treatments,” said John Wagner, MD, a pioneer in the field of umbilical cord blood transplantation.
“To date, our clinical data from trials demonstrated that correction of immune dysfunctions by Stem Cell Educator Therapy leads to the restoration of pancreatic islet β-cell function in long-standing T1D and T2D Chinese subjects. In collaboration with CORD:USE, we are going to submit the FDA application for the approval of clinical trials in the United States,” said Dr. Zhao.
“We are pleased that the high-quality cord blood samples obtained from CORD:USE will allow the scientific and clinical studies to continue that may in the near future allow cord blood to be used as a source of cell therapy to effectively treat patients with diabetes and autoimmune diseases,” said Dr. Hal Broxmeyer, who is recognized as a founder of the field of cord blood banking and transplantation.
About CORD:USE Cord Blood Bank, Inc.
CORD:USE Cord Blood Bank, headquartered in Orlando, Florida operates both leading high quality public and family cord blood banks. CORD:USE Cord Blood Bank has entered into agreements with hospitals across the country to provide mothers the option to donate their babies’ cord blood. CORD:USE Public Cord Blood Bank is one of the highest quality cord blood banks that has been chosen and partially funded by HRSA, of the U.S. Department of Health and Human Services, to help build the National Cord Blood Inventory. CORD:USE Family Cord Blood Bank uses the same highly advanced technologies as does their public bank. No other bank uses this combination of advanced technologies to protect cord blood. CORD:USE’s advanced technologies make it possible for them to privately store cord blood units for expectant parents from anywhere in the country and from around the world. Cord blood stem cells have been used successfully in the treatment of over 70 blood cancers and diseases. CORD:USE distributes cord blood units to transplanters, throughout the country and the world, as a critical component in their patients’ treatment. For more information, please visit our website www.corduse.com, or contact Michael Ernst at 407.667.3000.
About Tianhe Stem Cell Biotechnologies Inc.
Tianhe Stem Cell Biotechnologies Inc., an Illinois corporation, has licensed a series of patented technologies on human cord blood-derived multipotent stem cells (CB-SCs) from University of Illinois at Chicago (UIC), including the key technology Stem Cell Educator therapy. Tianhe focuses on the application of Stem Cell Educator therapy to treat diabetes and other autoimmune diseases. Tianhe is leading an international multicenter Phase II clinical trial in T1D. For more information, please visit our website www.tianhecell.com.
Logo – http://photos.prnasia.com/prnh/20141001/8521405388LOGO
— Ventana is committed to accelerating the discovery and development of new cancer diagnostic tests that help determine the best course of therapy for each individual patient.
MOUNTAIN VIEW, Calif., Sept. 30, 2014 /PRNewswire/ — Based on its recent analysis of the oncology tissue diagnostics market, Frost & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, with the 2014 North American Frost & Sullivan Award for Technology Innovation Leadership. Adherence to strict quality practices along with a focus on innovation and improving patient safety have made Ventana a global leader in tissue-based cancer diagnostic solutions for patients worldwide.
Click here for the full multimedia experience of this release – http://ow.ly/BMQZv
As a leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 220 cancer tests with related instruments for 90 countries, and most importantly, for the four million people afflicted with cancer each year. The company is committed to accelerating the discovery and development of new cancer diagnostic tests that allow pathologists to analyze patient samples at the molecular level to help determine the best course of therapy for each individual patient.
“Ventana’s ability to discover new technology and then develop it into first-ever products aligns with the Blue Ocean Strategy for creating new markets,” noted Frost & Sullivan Research Analyst, Divyaa Ravishankar “For instance, it pioneered automated staining, and was an early leader in the areas of biomarker detection chemistry and companion diagnostics. It is still the only company to provide such a wide portfolio of FDA-approved or cleared assays and algorithms.”
Making the most of Roche’s worldwide infrastructure, which includes significant markets not yet served, Ventana has continued to expand its global install base of automated platforms that run advanced cancer diagnostic tests and has achieved impressive growth for the past five years. Since 2002 Ventana has worked with more than 45 biopharmaceutical partners over the past decade and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.
Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impact both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry and the positive impact on brand perception.
Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.
About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. (“VMSI”) (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company’s intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to help reduce errors, support diagnosis and enable informed treatment decisions by anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of “companion diagnostics” to identify the patients most likely to respond favorably to specific therapies. VENTANA and the VENTANA logo are trademarks of Roche.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation
Contact:
Mireya Espinoza
P: +1-210-247-3870
F: +1-210-348-1003
E: mireya.espinoza@frost.com
– The World Fashion Week in Paris provides a platform for Malaysia to promote its upcoming Malaysia Fashion Week
– Datuk Professor Jimmy Choo to receive the World Fashion Organisation’s Lifetime Achievement Aw…
— Distributors are expected to deploy a multi-sector, multi-brand strategy to broaden their business, says Frost & Sullivan
LONDON, Sept. 30, 2014 /PRNewswire/ — Established and new medical technology service providers are increasingly looking at distributors to help penetrate the growing Eastern European medical devices market. Distribution models eliminate the need for a sales team and regional/local offices, reducing the costs incurred by medical technology service providers. This is a crucial advantage as medical technology service providers are operating within a budget-constrained healthcare environment.
New analysis from Frost & Sullivan, Medical Technologies Distributor Profiles in Eastern Europe, finds that the total Eastern European medical device industry earned revenues of $5.40 billion in 2013. Market revenues will continue to expand at a compound annual growth rate of 3.1% during the 2014-2018 period. The study covers simple distributors, importers and wholesalers, and fourth-party logistics companies.
For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/EU_PR_AZanchi_MA5C-54_23Sept14.
“By and large, distributors handle products across multiple medical device sectors and are able to effectively address the needs of large hospitals. Their relationships with key decision-makers, doctors and nurses of many hospitals can also help distributors secure supply contracts with hospitals more easily,” said Frost & Sullivan Healthcare Senior Research Analyst Parthasarathy Raghava. “This makes distributors integral to medical technology service providers’ strategies with hospitals across Eastern Europe.”
New opportunities will emerge for distributors in Eastern Europe as investment grows in private healthcare. Distributors can suggest specific strategies and project rationales that will help medical manufacturers strengthen their footprint in the private sector.
However, the unwillingness of several small, family-run distributors in the industry to consolidate and expand is creating a fragmented distribution market. Some distribution companies are also limited to small markets, as they do not have enough contacts among the main decision-makers in hospitals. As such, medical device distributors across Eastern Europe must focus on building business relationships and ensure they have sufficient resources to sell products. This will be crucial as global innovation and competition in the medical devices industry maintains the need for importing new technology in Eastern European countries.
“In due course, most distributors will adopt a multi-sector, multi-brand distribution strategy to expand their customer base and boost revenues,” noted Raghava. “This strategy will align well with the continuing trend of bulk purchasing by hospitals, which reduces operational complications and contains costs.”
Medical Technologies Distributor Profiles in Eastern Europe is part of the Advanced Medical Technologies Growth Partnership Service program. Frost & Sullivan’s related studies include: Automated Endoscope Reprocessor Market Trends in Western Europe, Optimisation and Efficiency Drive in Hospitals in Western Europe, Western and Eastern European Wound Care and Wound Closure Market, and Russian Arthroscopy Devices Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact
Anna Zanchi
Corporate Communications — Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com
SHANGHAI, September 30, 2014 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today…
BETHESDA, Md., September 30, 2014 /PRNewswire/ — Chindex International, Inc. (“Chindex” or the “Company”) (Nasdaq: CHDX) today announced the completion of its acquisition by Healthy Harmony Holdings, L.P. (“Healthy Harmony”) for $2…
2014 marks the first time The Economist’s innovation initiative has come to Asia in its 13-year history
HONG KONG, Sept. 30, 2014 /PRNewswire/ — Winners of The Economist’s prestigious Innovation awards 2014 will speak at The Economist Events’ Innovation Summit scheduled to take place at the JW Marriott Hong Kong on Friday, October 10th 2014. At the summit, the award winners will share their experiences and the lessons those hold for others. The awards, which recognises outstanding people who have made a proven innovation over the past decade, will be presented at a ceremony in Hong Kong the night before the summit. It will be the first time the ceremony has come to Asia. The award winners speaking at the summit include:
Nandan Nilekani, former head of the Unique Identification Authority of India (UIDAI), has won the Social & Economic Innovation Award for his leadership of the country’s national identity scheme.
Jay Keasling, Professor of Chemical Engineering at the University of California, Berkeley and Senior Faculty Scientist, Lawrence Berkeley National Laboratory for synthetic artemisinin used to treat malaria.”I was fortunate to lead a team of very talented scientists and engineers who worked long and hard to complete this high risk, high reward project,” said Dr Keasling. “Because of their efforts, the lives of many people will be saved and made better. Adoption of semisynthetic artemisinin is an important step forward in eradicating malaria.”
Pixar Animation Studios has won the Corporate Award for its ground-breaking computer animation tools, technology and feature films. Marc Greenberg, Vice President, Finance and Strategy, Pixar Animation Studios will speak on behalf of Pixar Animation Studios at the summit. “Pixar is honored to receive The Economist’s Corporate Innovation Award, which we accept on behalf of the studio’s incredible employees,” said Marc Greenberg. “Their creativity, commitment and drive are the source and foundation of all the company’s accomplishments.”
Renaud Laplanche, Founder and CEO of Lending Club, has won the Consumer Product Award for pioneering peer-to-peer consumer lending. “Our mission is to transform the banking system to make credit more affordable and investing more rewarding, and we’re gratified that so many investors and borrowers continue to find value in that commitment,” said Lending Club CEO Renaud Laplanche. “Having the impact of this disruption recognized and validated by the Economist Innovation Awards is a significant honor, and I’m excited to be recognized on behalf of all Lending Club team members.”
As in The Economist newspaper, the Innovation Summit will explore innovation through the lens of what matters to senior executives in Asia, without the hype. In addition to hearing from award-winning innovators, chief executives will share corporate stories of success and failure — with insight on how to learn from both. Entrepreneurs will share how to think like the competition in order to not be beaten by it. Participants will survey where disruption is heading in Asia and suggest how to avoid the shocks. The right role for government in spurring innovation will be examined and the latest breakthrough technologies will be revealed. Finally, The Economist will challenge the prevailing assumption that innovation is good and plentiful by debating the provocative notion that “We are not as innovative as we think”.
Other featured speakers include:
First time in Asia
Innovation is an increasingly global activity. No city, country or region has a monopoly on “new ideas that create value”, as The Economist likes to define it. The awards, the only awards presented by the newspaper, and the summit reflects that fact in its choice of location as well as its content.
“Unlike other awards ceremonies and conferences, our focus is not simply on promising innovations that might turn out to be important,” says Tom Standage, Online and Digital Editor of The Economist. “Rather, our focus is on proven innovations that have demonstrated their value — and the lessons that can be learned from them. In other words, we look backwards in order to look forwards.”
The Economist Intelligence Unit will be releasing a white paper Under the radar: Innovation in Asia evolves at the summit.
For further information on the awards and summit please visit the website: economistinsights.com/innovation2014.
Huawei and EY are sponsors for The Economist’s Innovation Awards and Summit 2014. InvestHK is the host sponsor.
About The Economist‘s Innovation Awards
In this annual awards programme, The Economist showcases creative people who dream up new ideas and turn them into reality. The newspaper invites its readers to nominate outstanding innovators in seven categories: Bioscience, Computing and Telecommunications, Consumer Products, Energy and the Environment, Process and Service Innovation, Social and Economic Innovation, and a special “no boundaries” category for innovations that span industries and sectors. In addition, the judges select the winner of the corporate award for innovation.
This year’s award judges included Tom Standage, Online and Digital Editor, The Economist; Vijay Vaitheeswaran, China Business and Finance Editor, The Economist; Hernando de Soto, Chairman, Institute for Liberty and Democracy; Hongyang Wang, Director, National Center for Liver Cancer, China Department of Health Science; and Lesa B. Roe, Director, Langley Research Center, NASA. To see the full judging panel, please visit the awards’ website: http://economistinsights.com/innovation2014.
Over the past 13 years, The Economist‘s Innovation Awards programme has recognised the work of the world’s leading entrepreneurs, thinkers, creators, scientists and innovators, including Steve Jobs, Mark Zuckerberg, Hernando de Soto and Elon Musk.
About Nandan Nilekani and the identity system
UIDAI was set up in 2009 with the aim of issuing everyone in India, especially the poorest residents in rural areas, a unique identification number. This would enable them to prove their identity in order to do things like open a bank account or get credit. Mr Nilekani led the team to create a biometric database of personal identities relying on fingerprints and iris scans.
The identity system can both reduce fraud and allow for the provision of vastly improved public services. When people have valid identification and bank accounts, government payments can go directly to them rather than into the pockets of intermediaries who have invented imaginary ghost workers or welfare recipients. Direct payments also allow people to be more mobile and leave their home village to seek work without forfeiting any benefits.
About Jay Keasling’s discovery
Artemisinin is the main ingredient used in drugs for treating malaria. But the natural supply of artemisinin is limited and inconsistent. Dr Keasling discovered how to synthesise small amounts of artemisinic acid, and formed a company named Amyris to develop the biological process. In December 2004 the Bill & Melinda Gates Foundation gave US$42.6 million to fund its research. Amyris was able to boost artemisinic acid production by a factor of 15. This led to large-scale production of semi-synthetic artemisinin.
Dr Keasling’s work has led to a major advance in the treatment of malaria, which affects an estimated 250 million people a year. It will increase and stabilise the supply of artemisinin, and lower the cost of this key malaria treatment.
About Pixar Animation Studios
Pixar has produced many significant technological breakthroughs, including computer graphics software that enables production of animated images of unparalleled quality, richness and vibrancy. Every Academy Award® winner for Visual Effects in the past 15 years has used Pixar’s suite of RenderMan products.
Pixar also changed the way animated films were made by launching its own short and then full-length animated feature films created entirely with computer technology. Its first feature film, “Toy Story,” was the highest-grossing movie of 1995. Pixar has earned 30 Academy Awards®, including seven for Best Animated feature, six Golden Globe Awards and 11 Grammy Awards.
About Renaud Laplanche and the Lending Club
In 2006, Renaud Laplanche noticed that if he carried a balance on his bank credit card he would pay 16.49% interest, yet the same bank would pay him interest of only 0.48% on his savings account. Intrigued by the huge spread, he built an online peer-to-peer marketplace called Lending Club that connects borrowers and investors, efficiently connecting the supply and demand of capital.
Most borrowers use Lending Club to access affordable credit. All of the loans offered through Lending Club’s marketplace feature fixed rates, fixed monthly payments, no hidden fees and no prepayment penalties. Lending Club delivers value to investors by providing them with the opportunity to earn attractive risk-adjusted returns. Between its launch and June 30th 2014, Lending Club facilitated $5 billion in loans.
Media Contact:
Stefanie Wong
Phone Number: +852-2837-4773
Email: Stefanie.wong@edelman.com